Evidence map›Paper›PMID 35129587›Full record

ArticleInvestigative ophthalmology & visual science2022

Effect of ATP-sensitive Potassium Channel Openers on Intraocular Pressure in Ocular Hypertensive Animal Models.

Uttio Roy Chowdhury, J Cameron Millar, Bradley H Holman, Kjersten J Anderson, Peter I Dosa, Gavin W Roddy, Michael P Fautsch

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Uttio Roy ChowdhuryDepartment of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
J Cameron MillarNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, United States.
Bradley H HolmanDepartment of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
Kjersten J AndersonDepartment of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
Peter I DosaInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, United States.
Gavin W RoddyDepartment of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
Michael P FautschDepartment of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
WinnMed · USMayo Clinic · USUniversity of Minnesota · USUniversity of North Texas Health Science Center · US

Funding

Intraocular pressure regulation via ATP-sensitive potassium channelsR01EY021727 · NEI · MAYO CLINIC ROCHESTER · PI FAUTSCH, MICHAEL P. · 2011 to 2021
$4.1M
Virally expressed Stanniocalcin-1 for long-term intraocular pressure reductionK08EY031758 · NEI · MAYO CLINIC ROCHESTER · PI RODDY, GAVIN W · 2021 to 2025
$778k
NEI NIH HHS K08 EY031758NEI NIH HHS R01 EY021727
6 · The paper itself

Abstract

Purpose: To evaluate the effect of ATP-sensitive potassium channel openers cromakalim prodrug 1 (CKLP1) and diazoxide on IOP in three independent mouse models of ocular hypertension. Methods: Baseline IOP was measured in TGFβ2 overexpression, steroid-induced, and iris dispersion (DBA/2J) ocular hypertension mouse models, followed by once daily eyedrop administration with CKLP1 (5 mM) or diazoxide (5 mM). The IOP was measured in conscious animals with a handheld rebound tonometer. Aqueous humor dynamics were assessed by a constant perfusion method. Effect of treatment on ocular tissues was evaluated by transmission electron microscopy. Results: CKLP1 decreased the IOP by 20% in TGFβ2 overexpressing mice (n = 6; P < 0.0001), 24% in steroid-induced ocular hypertensive mice (n = 8; P < 0.0001), and 43% in DBA/2J mice (n = 15; P < 0.0001). Diazoxide decreased the IOP by 32% in mice with steroid-induced ocular hypertension (n = 13; P < 0.0001) and by 41% in DBA/2J mice (n = 4; P = 0.005). An analysis of the aqueous humor dynamics revealed that CKLP1 decreased the episcleral venous pressure by 29% in TGFβ2 overexpressing mice (n = 13; P < 0.0001) and by 72% in DBA/2J mice (n = 4 control, 3 treated; P = 0.0002). Diazoxide lowered episcleral venous pressure by 35% in steroid-induced ocular hypertensive mice (n = 3; P = 0.03). Tissue histology and cell morphology appeared normal when compared with controls. Accumulation of extracellular matrix was reduced in CKLP1- and diazoxide-treated eyes in the steroid-induced ocular hypertension model. Conclusions: ATP-sensitive potassium channel openers CKLP1 and diazoxide effectively decreased the IOP in ocular hypertensive animal models by decreasing the episcleral venous pressure, supporting a potential therapeutic application of these agents in ocular hypertension and glaucoma.

Indexed as

AnimalsAntihypertensive AgentsCromakalimDiazoxideDisease Models, AnimalEyeIntraocular PressureKATP ChannelsMiceMice, Inbred DBAMicroscopy, Electron, TransmissionOcular HypertensionOphthalmic SolutionsAntihypertensive AgentsCromakalimDiazoxideKATP ChannelsOphthalmic Solutions

Identifiers

PMID35129587
PMCPMC8822368
OpenAlexW4210832842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.